Clinical Network Services Acquires New Zealand Partner BELTAS' Business Assets
Clinical Network Services (CNS), an Australian based CRO offering integrated development services in the planning, implementation and delivery of Phase I and II trials, announced that it has acquired the business assets of its erstwhile New Zealand partner BELTAS, a CRO based in Auckland. Terms of the deal were not disclosed.
The acquisition of BELTAS’ business officially completed at the end of 2012 with BELTAS contracts and all clinical staff transferring to CNS. BELTAS will continue to provide GCP training in New Zealand.
Russell Neal, Managing Director of CNS commented: “2012 has been a tremendous year for CNS and has seen us grow significantly over the last 12 months, expand our regional CRA base so we can better service local sites in Perth and Melbourne as well as further bed down our BioDesk services. This acquisition continues our goal of widening our capabilities across Australia and New Zealand and by bringing together these two highly skilled clinical teams with years of collective experience we are able to offer our clients a truly regional solution.
At the same time, CNS announced that its BioDesk service launched a year ago at the Genesis conference in London, had been a huge success and already gaining a very positive international reputation. BioDesk is an intelligent product development planning and regulatory affairs service designed for biotech companies planning wishing to enter the clinic faster by virtue of creating and managing a pre-clinical programme that encompasses a globalised regulatory perspective whilst leveraging unique regional advantages.
Mark Reid, Associate Director, BioDesk & Regulatory Affairs, added: “2012 has been a remarkable year with BioDesk performing well beyond our expectations. There is an obvious need for biotechnology companies to obtain expert support in making the transition from ‘bench’ to the clinic and BioDesk aims to provide this capability – particularly for companies looking to trial their products in Australia or New Zealand.”
Mark Reid, Associate Director, BioDesk & Regulatory Affairs and Karen West, Director of Business Development of CNS, will be attending the Biotech Showcase 2013 in San Francisco, CA, USA on 7th to 10th January 2013.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
